<!DOCTYPE html><html lang="en" ><head><meta http-equiv="Content-Type" content="text/html; charset=UTF-8"><meta name="theme-color" media="(prefers-color-scheme: light)" content="#f7f7f7"><meta name="theme-color" media="(prefers-color-scheme: dark)" content="#1b1b1e"><meta name="apple-mobile-web-app-capable" content="yes"><meta name="apple-mobile-web-app-status-bar-style" content="black-translucent"><meta name="viewport" content="width=device-width, user-scalable=no initial-scale=1, shrink-to-fit=no, viewport-fit=cover" ><meta name="generator" content="Jekyll v4.3.2" /><meta property="og:title" content="Reproducibility of mRECIST in Measurement and Response Assessment for Hepatocellular Carcinoma Treated by Transarterial Chemoembolization" /><meta property="og:locale" content="en" /><meta name="description" content="Rationale and Objectives" /><meta property="og:description" content="Rationale and Objectives" /><link rel="canonical" href="https://clinicaltree.github.io/posts/reproducibility-of-mrecist-in-measurement-and-response-assessment-for-hepatocellular-carcinoma-treat/" /><meta property="og:url" content="https://clinicaltree.github.io/posts/reproducibility-of-mrecist-in-measurement-and-response-assessment-for-hepatocellular-carcinoma-treat/" /><meta property="og:site_name" content="Radiology Tree" /><meta property="og:type" content="article" /><meta property="article:published_time" content="2018-10-31T17:00:00+00:00" /><meta name="twitter:card" content="summary" /><meta property="twitter:title" content="Reproducibility of mRECIST in Measurement and Response Assessment for Hepatocellular Carcinoma Treated by Transarterial Chemoembolization" /><meta name="twitter:site" content="@twitter_username" /><meta name="google-site-verification" content="RFHVRgQqK0eGjftEMCTDhsDrR8cJ_ZYcfCX52gXW8KM" /> <script type="application/ld+json"> {"@context":"https://schema.org","@type":"BlogPosting","dateModified":"2023-04-10T03:59:08+00:00","datePublished":"2018-10-31T17:00:00+00:00","description":"Rationale and Objectives","headline":"Reproducibility of mRECIST in Measurement and Response Assessment for Hepatocellular Carcinoma Treated by Transarterial Chemoembolization","mainEntityOfPage":{"@type":"WebPage","@id":"https://clinicaltree.github.io/posts/reproducibility-of-mrecist-in-measurement-and-response-assessment-for-hepatocellular-carcinoma-treat/"},"url":"https://clinicaltree.github.io/posts/reproducibility-of-mrecist-in-measurement-and-response-assessment-for-hepatocellular-carcinoma-treat/"}</script><title>Reproducibility of mRECIST in Measurement and Response Assessment for Hepatocellular Carcinoma Treated by Transarterial Chemoembolization | Radiology Tree</title><link rel="apple-touch-icon" sizes="180x180" href="/assets/img/favicons/apple-touch-icon.png"><link rel="icon" type="image/png" sizes="32x32" href="/assets/img/favicons/favicon-32x32.png"><link rel="icon" type="image/png" sizes="16x16" href="/assets/img/favicons/favicon-16x16.png"><link rel="manifest" href="/assets/img/favicons/site.webmanifest"><link rel="shortcut icon" href="/assets/img/favicons/favicon.ico"><meta name="apple-mobile-web-app-title" content="Radiology Tree"><meta name="application-name" content="Radiology Tree"><meta name="msapplication-TileColor" content="#da532c"><meta name="msapplication-config" content="/assets/img/favicons/browserconfig.xml"><meta name="theme-color" content="#ffffff"><link rel="preconnect" href="https://fonts.googleapis.com" ><link rel="dns-prefetch" href="https://fonts.googleapis.com" ><link rel="preconnect" href="https://fonts.gstatic.com" crossorigin><link rel="dns-prefetch" href="https://fonts.gstatic.com" crossorigin><link rel="preconnect" href="https://fonts.googleapis.com" ><link rel="dns-prefetch" href="https://fonts.googleapis.com" ><link rel="preconnect" href="https://cdn.jsdelivr.net" ><link rel="dns-prefetch" href="https://cdn.jsdelivr.net" ><link rel="stylesheet" href="https://fonts.googleapis.com/css2?family=Lato&family=Source+Sans+Pro:wght@400;600;700;900&display=swap"><link rel="preconnect" href="https://www.google-analytics.com" crossorigin="use-credentials"><link rel="dns-prefetch" href="https://www.google-analytics.com"><link rel="preconnect" href="https://www.googletagmanager.com" crossorigin="anonymous"><link rel="dns-prefetch" href="https://www.googletagmanager.com"><link rel="stylesheet" href="https://cdn.jsdelivr.net/npm/bootstrap@4.6.2/dist/css/bootstrap.min.css"><link rel="stylesheet" href="https://cdn.jsdelivr.net/npm/@fortawesome/fontawesome-free@6.2.1/css/all.min.css"><link rel="stylesheet" href="/assets/css/style.css"><link rel="stylesheet" href="https://cdn.jsdelivr.net/npm/tocbot@4.20.1/dist/tocbot.min.css"><link rel="stylesheet" href="https://cdn.jsdelivr.net/npm/magnific-popup@1.1.0/dist/magnific-popup.min.css"> <script src="https://cdn.jsdelivr.net/npm/jquery@3.6.1/dist/jquery.min.js"></script> <script type="text/javascript"> class ModeToggle { static get MODE_KEY() { return "mode"; } static get MODE_ATTR() { return "data-mode"; } static get DARK_MODE() { return "dark"; } static get LIGHT_MODE() { return "light"; } static get ID() { return "mode-toggle"; } constructor() { if (this.hasMode) { if (this.isDarkMode) { if (!this.isSysDarkPrefer) { this.setDark(); } } else { if (this.isSysDarkPrefer) { this.setLight(); } } } let self = this; /* always follow the system prefers */ this.sysDarkPrefers.addEventListener('change', () => { if (self.hasMode) { if (self.isDarkMode) { if (!self.isSysDarkPrefer) { self.setDark(); } } else { if (self.isSysDarkPrefer) { self.setLight(); } } self.clearMode(); } self.notify(); }); } /* constructor() */ get sysDarkPrefers() { return window.matchMedia("(prefers-color-scheme: dark)"); } get isSysDarkPrefer() { return this.sysDarkPrefers.matches; } get isDarkMode() { return this.mode === ModeToggle.DARK_MODE; } get isLightMode() { return this.mode === ModeToggle.LIGHT_MODE; } get hasMode() { return this.mode != null; } get mode() { return sessionStorage.getItem(ModeToggle.MODE_KEY); } /* get the current mode on screen */ get modeStatus() { if (this.isDarkMode || (!this.hasMode && this.isSysDarkPrefer)) { return ModeToggle.DARK_MODE; } else { return ModeToggle.LIGHT_MODE; } } setDark() { $('html').attr(ModeToggle.MODE_ATTR, ModeToggle.DARK_MODE); sessionStorage.setItem(ModeToggle.MODE_KEY, ModeToggle.DARK_MODE); } setLight() { $('html').attr(ModeToggle.MODE_ATTR, ModeToggle.LIGHT_MODE); sessionStorage.setItem(ModeToggle.MODE_KEY, ModeToggle.LIGHT_MODE); } clearMode() { $('html').removeAttr(ModeToggle.MODE_ATTR); sessionStorage.removeItem(ModeToggle.MODE_KEY); } /* Notify another plugins that the theme mode has changed */ notify() { window.postMessage({ direction: ModeToggle.ID, message: this.modeStatus }, "*"); } flipMode() { if (this.hasMode) { if (this.isSysDarkPrefer) { if (this.isLightMode) { this.clearMode(); } else { this.setLight(); } } else { if (this.isDarkMode) { this.clearMode(); } else { this.setDark(); } } } else { if (this.isSysDarkPrefer) { this.setLight(); } else { this.setDark(); } } this.notify(); } /* flipMode() */ } /* ModeToggle */ const modeToggle = new ModeToggle(); </script><body data-topbar-visible="true"><div id="sidebar" class="d-flex flex-column align-items-end"><div class="profile-wrapper text-center"><div id="avatar"> <a href="/" class="mx-auto"> <img src="https://storage.googleapis.com/clinicalpub.com/images/favicon.png" alt="avatar" onerror="this.style.display='none'"> </a></div><div class="site-title"> <a href="/">Radiology Tree</a></div><div class="site-subtitle font-italic">Update every day the best and the lastest articles, books, journals, clinical cases, videos, images... for radiologist</div></div><ul class="w-100"><li class="nav-item"> <a href="/" class="nav-link"> <i class="fa-fw fas fa-home ml-xl-3 mr-xl-3 unloaded"></i> <span>HOME</span> </a><li class="nav-item"> <a href="/categories/" class="nav-link"> <i class="fa-fw fas fa-stream ml-xl-3 mr-xl-3 unloaded"></i> <span>CATEGORIES</span> </a><li class="nav-item"> <a href="/tags/" class="nav-link"> <i class="fa-fw fas fa-tag ml-xl-3 mr-xl-3 unloaded"></i> <span>TAGS</span> </a><li class="nav-item"> <a href="/archives/" class="nav-link"> <i class="fa-fw fas fa-archive ml-xl-3 mr-xl-3 unloaded"></i> <span>ARCHIVES</span> </a><li class="nav-item"> <a href="/about/" class="nav-link"> <i class="fa-fw fas fa-info-circle ml-xl-3 mr-xl-3 unloaded"></i> <span>ABOUT</span> </a></ul><div class="sidebar-bottom mt-auto d-flex flex-wrap justify-content-center align-items-center"> <button class="mode-toggle btn" aria-label="Switch Mode"> <i class="fas fa-adjust"></i> </button> <span class="icon-border"></span> <a href="https://github.com/clinicaltree" aria-label="github" target="_blank" rel="noopener noreferrer"> <i class="fab fa-github"></i> </a> <a href="https://twitter.com/twitter_username" aria-label="twitter" target="_blank" rel="noopener noreferrer"> <i class="fab fa-twitter"></i> </a> <a href="javascript:location.href = 'mailto:' + ['clinicalpub.team','gmail.com'].join('@')" aria-label="email" > <i class="fas fa-envelope"></i> </a> <a href="/feed.xml" aria-label="rss" > <i class="fas fa-rss"></i> </a></div></div><div id="topbar-wrapper"><div id="topbar" class="container d-flex align-items-center justify-content-between h-100 pl-3 pr-3 pl-md-4 pr-md-4"> <span id="breadcrumb"> <span> <a href="/"> Home </a> </span> <span>Reproducibility of mRECIST in Measurement and Response Assessment for Hepatocellular Carcinoma Treated by Transarterial Chemoembolization</span> </span> <i id="sidebar-trigger" class="fas fa-bars fa-fw"></i><div id="topbar-title"> Post</div><i id="search-trigger" class="fas fa-search fa-fw"></i> <span id="search-wrapper" class="align-items-center"> <i class="fas fa-search fa-fw"></i> <input class="form-control" id="search-input" type="search" aria-label="search" autocomplete="off" placeholder="Search..."> </span> <span id="search-cancel" >Cancel</span></div></div><div id="main-wrapper" class="d-flex justify-content-center"><div id="main" class="container pl-xl-4 pr-xl-4"><div class="row"><div id="core-wrapper" class="col-12 col-lg-11 col-xl-9 pr-xl-4"><div class="post pl-1 pr-1 pl-md-2 pr-md-2"><h1 data-toc-skip>Reproducibility of mRECIST in Measurement and Response Assessment for Hepatocellular Carcinoma Treated by Transarterial Chemoembolization</h1><div class="post-meta text-muted"> <span> Posted <em class="" data-ts="1541005200" data-df="ll" data-toggle="tooltip" data-placement="bottom"> Oct 31, 2018 </em> </span> <span> Updated <em class="" data-ts="1681099148" data-df="ll" data-toggle="tooltip" data-placement="bottom"> Apr 10, 2023 </em> </span><div class="d-flex justify-content-between"> <span> By <em> <a href="">Moon Hyung Choi MD</a> </em>, <em> <a href="">Ga Eun Park MD</a> </em>, <em> <a href="">Soon Nam Oh MD</a> </em>, <em> <a href="">Michael Yong Park MD</a> </em>, <em> <a href="">Sung Eun Rha MD</a> </em>, <em> <a href="">Young Joon Lee MD</a> </em>, <em> <a href="">Seung Eun Jung MD</a> </em>, <em> <a href="">Joon-Il Choi MD</a> </em> </span><div> <span class="readtime" data-toggle="tooltip" data-placement="bottom" title="2719 words"> <em>15 min</em> read</span></div></div></div><div class="post-content"><h2 id="rationale-and-objectives"><span class="mr-2">Rationale and Objectives</span><a href="#rationale-and-objectives" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><p>To evaluate the reproducibility of Modified Response Evaluation Criteria in Solid Tumors (mRECIST) for hepatocellular carcinoma (HCC) after transarterial chemoembolization (TACE) using multiphasic computed tomography.</p><h2 id="materials-and-methods"><span class="mr-2">Materials and methods</span><a href="#materials-and-methods" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><p>The institutional review board approved this retrospective study. We evaluated 97 patients who underwent TACE (60 conventional TACE [cTACE] and 37 drug-eluting bead TACE [DEB-TACE]) for HCC from 2010 to 2014. Four radiologists evaluated pairs of dynamic liver CTs scanned within 2 months before and after TACE based on mRECIST. Assessment of intra- or interobserver reproducibility for response categorization and sum of long diameter were evaluated using weighted kappa statistics (κ) and intraclass correlation coefficients, respectively. The relationship between concordance of target lesion selection and agreement of target lesion response was evaluated using Fisher exact test.</p><h2 id="results"><span class="mr-2">Results</span><a href="#results" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><p>Intraobserver reproducibility for overall response was moderate to excellent (κ = 0.525–0.865). Interobserver reproducibility was improved on the second review compared to the first review and it was good in both treatment groups (κ = 0.627 for cTACE and 0.602 for DEB-TACE). Between the two treatment methods, intra- or interobserver reproducibility was better after cTACE than DEB-TACE. Intraclass correlation coefficients for sum of long diameter measurement showed excellent intra- or interobserver reproducibility. The concordance rate of target lesion selection was significantly higher for patients with radiologists’ agreement for target lesion response than patients with disagreed response ( <em>P</em> = .003).</p><h2 id="conclusions"><span class="mr-2">Conclusions</span><a href="#conclusions" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><p>The intra- and interobserver reproducibility of mRECIST in patients with HCC after TACE was moderate to excellent, and the reproducibility was slightly better after cTACE than DEB-TACE.</p><h2 id="introduction"><span class="mr-2">Introduction</span><a href="#introduction" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><p>Transarterial chemoembolization (TACE) is the standard treatment for patients with hepatocellular carcinoma (HCC) who are classified as Barcelona clinic liver cancer stage B . Conventional transarterial chemoembolization (cTACE) using anticancer drugs with oily radio-opaque contrast medium and drug-eluting bead TACE (DEB-TACE) using beads loaded with chemotherapy agent are the two most commonly performed treatments for the intermediate stage patients with HCC . Treatment response after TACE is usually evaluated based on radiological examinations such as computed tomography (CT) or magnetic resonance imaging . Accurate evaluation of treatment response is important to predict patient prognosis and determine the next treatment methods .</p><p>Response Evaluation Criteria in Solid Tumors (RECIST) is the standard method of evaluating treatment response in solid tumors. However, as RECIST is a size-based method and does not take into account tumor necrosis after treatment, limitations in HCC after the locoregional treatments or systemic therapy using molecular-targeting agents were reported, and modified RECIST (mRECIST) was developed . mRECIST is based on tumor viability, which is represented by enhancement on arterial phase imaging, as a decrease in tumor load is more important than a reduction in tumor size in mRECIST.</p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><h2 id="materials-and-methods-1"><span class="mr-2">Materials and Methods</span><a href="#materials-and-methods-1" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><h2 id="patients"><span class="mr-2">Patients</span><a href="#patients" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://storage.googleapis.com/dl.dentistrykey.com/clinical/ReproducibilityofmRECISTinMeasurementandResponseAssessmentforHepatocellularCarcinomaTreatedbyTransarterialChemoembolization/0_1s20S1076633218300990.jpg" class="popup img-link "><img data-src="https://storage.googleapis.com/dl.dentistrykey.com/clinical/ReproducibilityofmRECISTinMeasurementandResponseAssessmentforHepatocellularCarcinomaTreatedbyTransarterialChemoembolization/0_1s20S1076633218300990.jpg" alt="Figure 1, Flowchart for the case accrual process." class="lazyload" data-proofer-ignore></a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://storage.googleapis.com/dl.dentistrykey.com/clinical/ReproducibilityofmRECISTinMeasurementandResponseAssessmentforHepatocellularCarcinomaTreatedbyTransarterialChemoembolization/1_1s20S1076633218300990.jpg" class="popup img-link "><img data-src="https://storage.googleapis.com/dl.dentistrykey.com/clinical/ReproducibilityofmRECISTinMeasurementandResponseAssessmentforHepatocellularCarcinomaTreatedbyTransarterialChemoembolization/1_1s20S1076633218300990.jpg" alt="Figure 2, Fifty-four-year-old woman with hepatocellular carcinoma who underwent drug-eluting bead transarterial embolization (DEB-TACE). ( a ) Initial computed tomography (CT) image shows an arterial enhancing mass at segment 8 of the liver. ( b ) CT scan obtained after DEB-TACE shows necrotic change in most of the tumor and a residual small enhancing portion at the left side of the mass. All radiologists evaluated the response of this lesion as a partial response." class="lazyload" data-proofer-ignore></a></p><p><a href="https://storage.googleapis.com/dl.dentistrykey.com/clinical/ReproducibilityofmRECISTinMeasurementandResponseAssessmentforHepatocellularCarcinomaTreatedbyTransarterialChemoembolization/2_1s20S1076633218300990.jpg" class="popup img-link "><img data-src="https://storage.googleapis.com/dl.dentistrykey.com/clinical/ReproducibilityofmRECISTinMeasurementandResponseAssessmentforHepatocellularCarcinomaTreatedbyTransarterialChemoembolization/2_1s20S1076633218300990.jpg" alt="Figure 3, Sixty-nine-year-old woman with hepatocellular carcinoma who underwent conventional transarterial embolization (cTACE). ( a ) Initial computed tomography (CT) image shows an arterial enhancing mass with lobulated contour in the right hepatic dome. ( b ) CT scan obtained after cTACE shows patchy lipiodol retention and a multifocal residual enhancing portion in the mass. Two radiologists evaluated treatment response as a partial response and the other two radiologists as stable disease." class="lazyload" data-proofer-ignore></a></p><p><a href="https://storage.googleapis.com/dl.dentistrykey.com/clinical/ReproducibilityofmRECISTinMeasurementandResponseAssessmentforHepatocellularCarcinomaTreatedbyTransarterialChemoembolization/3_1s20S1076633218300990.jpg" class="popup img-link "><img data-src="https://storage.googleapis.com/dl.dentistrykey.com/clinical/ReproducibilityofmRECISTinMeasurementandResponseAssessmentforHepatocellularCarcinomaTreatedbyTransarterialChemoembolization/3_1s20S1076633218300990.jpg" alt="Figure 4, Sixty-two-year-old man with hepatocellular carcinoma who underwent drug-eluting bead transarterial embolization (DEB-TACE). ( a ) Initial computed tomography (CT) image shows arterial enhancing mass with lobulated contour in segment 6 of the liver. ( b ) CT scan obtained after DEB-TACE shows a peripheral enhancing portion with an irregular shape. Two radiologists considered the nodular enhancing portion as a single, confluent area and they evaluated treatment response as stable disease. ( c ) The other two radiologists considered that the nodular enhancing portion consisted of two separate areas, so they only measured the diameter of one area and evaluated treatment response as a partial response." class="lazyload" data-proofer-ignore></a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><h2 id="tace-protocol"><span class="mr-2">TACE Protocol</span><a href="#tace-protocol" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><h2 id="ct-image-acquisition"><span class="mr-2">CT Image Acquisition</span><a href="#ct-image-acquisition" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><h2 id="image-analysis"><span class="mr-2">Image Analysis</span><a href="#image-analysis" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><h2 id="data-analyses-and-statistical-methods"><span class="mr-2">Data Analyses and Statistical Methods</span><a href="#data-analyses-and-statistical-methods" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><h2 id="results-1"><span class="mr-2">Results</span><a href="#results-1" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><h2 id="patient-characteristics"><span class="mr-2">Patient Characteristics</span><a href="#patient-characteristics" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p>TABLE 1</p><p>Baseline Characteristics of Patients</p><p>All ( <em>n</em> = 97) cTACE ( <em>n</em> = 60) DEB-TACE ( <em>n</em> = 37)<em>P</em> Value Gender (M:F) 72:25 42:18 30:7 .226 Age (mean ± SD) 64.5 ± 10.7 65.9 ± 11.0 64.8 ± 10.3 .615 Etiology (%) .229 HBV 55 (56.7) 35 (58.3) 20 (54.1) HCV 10 (10.3) 3 (5.0) 7 (18.9) Alcohol 13 (13.4) 8 (13.3) 5 (13.5) NANBNC 14 (4.4) 11 (18.3) 3 (8.1) NASH 1 (1.0) 1 (1.7) 0 (0) HBV + alcohol 4 (4.1) 2 (3.3) 2 (5.4) Diagnosis (%) .174 Imaging 87 (89.7) 56 (93.3) 31 (83.8) Biopsy 10 (10.3) 4 (6.7) 6 (16.2) Interval, pre- and post-treatment CT 50.6 ± 18.7 49.9 ± 18.5 51.6 ± 19.3 .674 Interval, pre-treatment CT and treatment 34.8 ± 14.4 34.2 ± 13.9 35.9 ± 15.2 .582 Child-Pugh score 5.5 ± 0.8 5.8 ± 0.8 5.4 ± 0.9 .556 Total bilirubin 1.0 ± 1.0 1.0 ± 1.1 1.0 ± 1.0 .950 Direct bilirubin 0.4 ± 0.7 0.5 ± 0.9 0.3 ± 0.2 .233 AST 55.0 ± 55.1 59.9 ± 45.7 48.7 ± 68.0 .426 ALT 49.3 ± 70.3 47.8 ± 59.3 51.7 ± 86.1 .810 Albumin 4.2 ± 3.7 4.4 ± 4.7 3.9 ± 0.5 .467 Creatinine 1.0 ± 1.0 1.0 ± 0.8 1.1 ± 1.3 .605 WBC 5.3 ± 2.2 5.4 ± 2.2 5.0 ± 2.1 .333 Hemoglobin 13.2 ± 1.9 13.1 ± 1.9 13.5 ± 1.8 .279 Platelet 155.0 ± 78.2 161.6 ± 85.3 144.2 ± 64.6 .258 INR 1.7 ± 1.1 1.1 ± 0.1 1.1 ± 0.1 .546 AFP 2893.6 ± 15279.2 3906.0 ± 19282.5 1251.8 ± 2949.9 .299 PIVKA-II 7236.2 ± 23422.1 10105.7 ± 29257.7 2582.9 ± 4901.4 .125</p><p>AFP, alpha fetoprotein; ALT, alanine transaminase; AST, aspartate transaminase; cTACE, conventional transarterial chemoemobolization; DEB-TACE, drug-eluting bead transarterial chemoembolization; HBV, hepatitis B virus; HCV, hepatitis C virus; INR, international normalized ratio; NANBNC, non-A, non-B, non-C hepatitis; PIVKA-II, Protein induced by vitamin K absence or antagonist-II; WBC, white blood cell.</p><p>Data are presented as mean ± standard deviation for continuous values and number with proportion in parentheses for categorical values.</p><p><em>P</em> values were calculated using the independent <em>t</em> test or the chi-square test.</p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><h2 id="intraobserver-reproducibility"><span class="mr-2">Intraobserver Reproducibility</span><a href="#intraobserver-reproducibility" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p>TABLE 2</p><p>Intraobserver Reproducibility</p><p>All Patients cTACE DEB-TACE Reader 1 Overall 0.865 0.859 0.872 Target lesion 0.853 0.851 0.847 Nontarget lesion 0.782 0.860 0.600 Reader 2 Overall 0.615 0.588 0.518 Target lesion 0.616 0.547 0.767 Nontarget lesion 0.657 0.651 0 Reader 3 Overall 0.525 0.552 0.471 Target lesion 0.628 0.641 0.564 Nontarget lesion 0.622 0.714 0.333 Reader 4 Overall 0.569 0.648 0.407 Target lesion 0.626 0.683 0.510 Nontarget lesion 0 0 0</p><p>Numbers are the weighted kappa values.</p><p>cTACE, conventional transarterial chemoemobolization; DEB-TACE, drug-eluting bead transarterial chemoembolization.</p><p>TABLE 3</p><p>Intraobserver Reproducibility of Sum of Long Diameter (SLD) of Viable Tumor</p><p>All Patients cTACE DEB-TACE SLD SLD SLD First Review Second Review ICC \* First Review Second Review ICC \* First Review Second Review ICC \* Reader 1 Pretreatment (cm) 5.96 ± 5.17 5.64 ± 4.80 0.979 6.84 ± 6.14 6.58 ± 5.67 0.980 5.22 ± 2.55 5.08 ± 2.77 0.968 Posttreatment (cm) 2.80 ± 5.58 2.50 ± 5.27 0975 3.54 ± 6.94 3.16 ± 6.72 0.975 1.94 ± 2.10 1.79 ± 2.17 0.967 Change (%) 34.7 ± 41.1 33.2 ± 44.5 0.954 36.6 ± 46.3 29.2 ± 45.6 0.957 35.1 ± 32.5 32.9 ± 37.7 0.946 Reader 2 Pretreatment (cm) 6.74 ± 5.73 6.39 ± 4.28 0.969 7.99 ± 6.89 7.74 ± 5.77 0.970 5.03 ± 2.42 4.91 ± 2.26 0.947 Posttreatment (cm) 3.64 ± 5.90 3.80 ± 5.51 0.971 4.75 ± 7.22 5.26 ± 6.74 0.974 2.07 ± 2.27 1.90 ± 2.33 0.897 Change (%) 40.6 ± 39.7 45.7 ± 41.0 0.890 39.9 ± 39.8 50.1 ± 41.5 0.895 34.9 ± 34.3 33.1 ± 37.7 0.900 Reader 3 Pretreatment (cm) 5.89 ± 4.31 5.92 ± 3.81 0.931 6.60 ± 5.00 6.64 ± 4.33 0.946 4.29 ± 2.16 4.67 ± 2.43 0.777 vPosttreatment (cm) 2.38 ± 4.56 2.42 ± 4.36 0.951 2.95 ± 5.33 2.90 ± 5.15 0.968 1.30 ± 2.11 1.59 ± 2.40 0.762 Change (%) 28.8 ± 38.7 29.6 ± 39.4 0.839 32.7 ± 41.9 30.7 ± 41.6 0.912 25.6 ± 37.6 30.1 ± 38.3 0.685 Reader 4 Pretreatment (cm) 6.20 ± 4.35 6.04 ± 3.88 0.874 7.26 ± 5.08 7.45 ± 4.51 0.866 4.86 ± 2.24 4.98 ± 2.08 0.864 Posttreatment (cm) 3.59 ± 5.26 3.19 ± 4.86 0.882 4.66 ± 6.41 4.02 ± 6.12 0.875 2.13 ± 2.06 2.09 ± 2.03 0.926 Change (%) 45.5 ± 42.7 41.0 ± 41.0 0.858 48.3 ± 47.0 37.3 ± 44.3 0.833 43.0 ± 34.9 39.8 ± 35.8 0.922</p><p>cTACE, conventional transarterial chemoembolization; DEB-TACE, drug-eluting beads-transarterial chemoembolization; ICC, intraclass correlation coefficient; SLD, sum of the longest diameter of the target lesions.</p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><h2 id="interobserver-reproducibility"><span class="mr-2">Interobserver Reproducibility</span><a href="#interobserver-reproducibility" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p>TABLE 4</p><p>Interobserver Reproducibility of Response Evaluation and SLD Measurement</p><p>All cTACE DEB-TACE First Review Second Review First Review Second Review First Review Second Review Overall response categorization 0.577 0.618 0.685 0.627 0.340 0.602 Target lesion response categorization 0.618 0.627 0.638 0.625 0.583 0.643 SLD, Before treatment \* 0.941 0.957 0.939 0.957 0.922 0.924 SLD, After treatment \* 0.947 0.959 0.946 0.968 0.925 0.902 SLD, Change (%) \* 0.907 0.909 0.931 0.946 0.896 0.909 Nontarget lesion response categorization 0.307 0.795 0.323 0.798 0 0.285</p><p>cTACE, conventional transarterial chemoembolization; DEB-TACE, drug-eluting beads-transarterial chemoembolization; SLD, sum of the longest diameter of the target lesions.</p><p>Reproducibility of response categorization: weighted kappa values.</p><p>Reproducibility of SLD: intraclass correlation coefficient.</p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><h2 id="causes-of-the-variability-in-overall-response"><span class="mr-2">Causes of the Variability in Overall Response</span><a href="#causes-of-the-variability-in-overall-response" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><h2 id="discussion"><span class="mr-2">Discussion</span><a href="#discussion" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><h2 id="acknowledgment"><span class="mr-2">Acknowledgment</span><a href="#acknowledgment" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><h2 id="appendix"><span class="mr-2">Appendix</span><a href="#appendix" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p>Table A.1</p><p>Overall Response Assessment in mRECIST</p><p>Target Lesions Nontarget Lesions New Lesions Overall Response CR CR No CR CR IR/SD No PR PR Non-PD No PR SD Non-PD No SD PD Any Yes or no PD Any PD Yes or no PD Any Any Yes PD</p><p>mRECIST, modified Response Evaluation Criteria in Solid Tumors; CR, complete response; PR, partial response; IR, incomplete response; SD, stable disease; PD, progressive disease.</p><p>Table A.2</p><p>Differences in Proportions of Agreement Between Target Lesion, Nontarget Lesion, and Overall Response</p><p>Overall response Agreement Disagreement_P_ Value 4 categories (CR, PR, SD, PD) Target Agreement 29 6<strong>&lt;.001</strong> Disagreement 4 58 Nontarget Agreement 25 34<strong>.047</strong> Disagreement 8 30 New lesion Agreement 10 54 .766 Disagreement 4 29 2 categories (Responder, nonresponder) Target Agreement 60 7<strong>&lt;.001</strong> Disagreement 4 26 Nontarget Agreement 49 21 .233 Disagreement 15 12 New lesion Agreement 57 26 .224 Disagreement 7 7</p><p>CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease. <em>P</em> values are calculated using the Fisher’s exact test.</p><p>Table A.3</p><p>Details of Response Assessment From Four Readers for Patients They Disagreed on Showing Overall Response in the Dichotomized Evaluation of the Second Review</p><p><a href="APKAICLNFGBCWWYGVIZQ" class="popup img-link "><img data-src="https://d1niluoi1dd30v.cloudfront.net/10766332/S1076633218X00105/S1076633218300990/fx1.jpg?Signature=Skr2vNEk8x7n-XBuk93c20uY8V4ZL8y0pZDZ%7EcTIpxjAjYfNBwzAuIe-oycNp26Nt8p%7ESDbGS2hPGsVGNF2zZJwWn-hPrXN11Tit32XO%7EDKT%7Ej9E-JGi9u8tkTDyjWwnsWdDnd0l%7Efyrb%7EbvSWl0CUzLUxoZV7OKUo%7EXHEZkDQ8_&amp;Expires=1669604700&amp;Key-Pair-Id=APKAICLNFGBCWWYGVIZQ" alt="" class="lazyload" data-proofer-ignore></a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><h2 id="references"><span class="mr-2">References</span><a href="#references" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><ul><li><p>1. Bruix J., Sherman M.: Management of hepatocellular carcinoma: an update. Hepatology 2011; 53: pp. 1020-1022.</p><li><p>2. Casadaban L.C., Minocha J., Bui J.T., et. al.: Conventional ethiodized oil transarterial chemoembolization for treatment of hepatocellular carcinoma: contemporary single-center review of clinical outcomes. AJR Am J Roentgenol 2016; 206: pp. 645-654.</p><li><p>3. Duran R., Chapiro J., Schernthaner R.E., et. al.: Systematic review of catheter-based intra-arterial therapies in hepatocellular carcinoma: state of the art and future directions. Br J Radiol 2015; 88: pp. 20140564.</p><li><p>4. Kallini J.R., Miller F.H., Gabr A., et. al.: Hepatic imaging following intra-arterial embolotherapy. Abdom Radiol (NY) 2016; 41: pp. 600-616.</p><li><p>5. Bruix J., Reig M., Rimola J., et. al.: Clinical decision making and research in hepatocellular carcinoma: pivotal role of imaging techniques. Hepatology 2011; 54: pp. 2238-2244.</p><li><p>6. Gillmore R., Stuart S., Kirkwood A., et. al.: EASL and mRECIST responses are independent prognostic factors for survival in hepatocellular cancer patients treated with transarterial embolization. J Hepatol 2011; 55: pp. 1309-1316.</p><li><p>7. Hyun D., Shin S.W., Cho S.K., et. al.: Efficacy of RECIST and mRECIST criteria as prognostic factors in patients undergoing repeated iodized oil chemoembolization of intermediate stage hepatocellular carcinoma. Acta Radiol 2015; 56: pp. 1437-1445.</p><li><p>8. Kim B.K., Kim K.A., Park J.Y., et. al.: Prospective comparison of prognostic values of modified response evaluation criteria in solid tumours with European Association for the Study of the liver criteria in hepatocellular carcinoma following chemoembolisation. Eur J Cancer 2013; 49: pp. 826-834.</p><li><p>9. Kim D.J., Clark P.J., Heimbach J., et. al.: Recurrence of hepatocellular carcinoma: importance of mRECIST response to chemoembolization and tumor size. Am J Transplant 2014; 14: pp. 1383-1390.</p><li><p>10. Sato Y., Watanabe H., Sone M., et. al.: Tumor response evaluation criteria for HCC (hepatocellular carcinoma) treated using TACE (transcatheter arterial chemoembolization): RECIST (response evaluation criteria in solid tumors) version 1.1 and mRECIST (modified RECIST): JIVROSG-0602. Ups J Med Sci 2013; 118: pp. 16-22.</p><li><p>11. Shim J.H., Han S., Shin Y.M., et. al.: Optimal measurement modality and method for evaluation of responses to transarterial chemoembolization of hepatocellular carcinoma based on enhancement criteria. J Vasc Interv Radiol 2013; 24: pp. 316-325.</p><li><p>12. Yeo D.M., Choi J.I., Lee Y.J., et. al.: Comparison of RECIST, mRECIST, and Choi Criteria for early response evaluation of hepatocellular carcinoma after transarterial chemoembolization using drug-eluting beads. J Comput Assist Tomogr 2014; 38: pp. 391-397.</p><li><p>13. Kim M.N., Kim B.K., Han K.H., et. al.: Evolution from WHO to EASL and mRECIST for hepatocellular carcinoma: considerations for tumor response assessment. Expert Rev Gastroenterol Hepatol 2015; 9: pp. 335-348.</p><li><p>14. Yaghmai V., Besa C., Kim E., et. al.: Imaging assessment of hepatocellular carcinoma response to locoregional and systemic therapy. AJR Am J Roentgenol 2013; 201: pp. 80-96.</p><li><p>15. Shim J.H., Lee H.C., Kim S.O., et. al.: Which response criteria best help predict survival of patients with hepatocellular carcinoma following chemoembolization? A validation study of old and new models. Radiology 2012; 262: pp. 708-718.</p><li><p>16. Lencioni R., Llovet J.M.: Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis 2010; 30: pp. 52-60.</p><li><p>17. Liu Q., Li A., Sun S., et. al.: The true role of mRECIST guideline: does it really estimate viable tumor or merely improve accuracy in hepatocellular carcinoma response evaluation?. J BUON 2014; 19: pp. 398-405.</p><li><p>18. Seyal A.R., Gonzalez-Guindalini F.D., Arslanoglu A., et. al.: Reproducibility of mRECIST in assessing response to transarterial radioembolization therapy in hepatocellular carcinoma. Hepatology 2015; 62: pp. 1111-1121.</p><li><p>19. Kim H.C., Kim A.Y., Han J.K., et. al.: Hepatic arterial and portal venous phase helical CT in patients treated with transcatheter arterial chemoembolization for hepatocellular carcinoma: added value of unenhanced images. Radiology 2002; 225: pp. 773-780.</p><li><p>20. Dioguardi Burgio M., Ronot M., Bruno O., et. al.: Correlation of tumor response on computed tomography with pathological necrosis in hepatocellular carcinoma treated by chemoembolization before liver transplantation. Liver Transpl 2016; 22: pp. 1491-1500.</p><li><p>21. Bargellini I., Bozzi E., Campani D., et. al.: Modified RECIST to assess tumor response after transarterial chemoembolization of hepatocellular carcinoma: CT-pathologic correlation in 178 liver explants. Eur J Radiol 2013; 82: pp. e212-e218.</p><li><p>22. Chiu R.Y., Yap W.W., Patel R., et. al.: Hepatocellular carcinoma post embolotherapy: imaging appearances and pitfalls on computed tomography and magnetic resonance imaging. Can Assoc Radiol J 2016; 67: pp. 158-172.</p><li><p>23. Chung W.S., Lee K.H., Park M.S., et. al.: Enhancement patterns of hepatocellular carcinoma after transarterial chemoembolization using drug-eluting beads on arterial phase CT images: a pilot retrospective study. AJR Am J Roentgenol 2012; 199: pp. 349-359.</p><li><p>24. McErlean A., Panicek D.M., Zabor E.C., et. al.: Intra- and interobserver variability in CT measurements in oncology. Radiology 2013; 269: pp. 451-459.</p><li><p>25. Boatta E., Corona M., Cannavale A., et. al.: Endovascular treatment of hepatocellular carcinoma with drug eluting microparticles (DC-Beads): CT evaluation of response to the treatment. Indian J Radiol Imaging 2013; 23: pp. 126-133.</p><li><p>26. Tacher V., Lin M., Duran R., et. al.: Comparison of existing response criteria in patients with hepatocellular carcinoma treated with transarterial chemoembolization using a 3D quantitative approach. Radiology 2016; 278: pp. 275-284.</p><li><p>27. Donati O.F., Do R.K., Hotker A.M., et. al.: Interreader and inter-test agreement in assessing treatment response following transarterial embolization for hepatocellular carcinoma. Eur Radiol 2015; 25: pp. 2779-2788.</p><li><p>28. Keil S., Barabasch A., Dirrichs T., et. al.: Target lesion selection: an important factor causing variability of response classification in the response evaluation criteria for solid tumors 1.1. Invest Radiol 2014; 49: pp. 509-517.</p><li><p>29. Feinstein A.R., Cicchetti D.V.: High agreement but low kappa: I. The problems of two paradoxes. J Clin Epidemiol 1990; 43: pp. 543-549.</p><li><p>30. Cicchetti D.V., Feinstein A.R.: High agreement but low kappa: II. Resolving the paradoxes. J Clin Epidemiol 1990; 43: pp. 551-558.</p><li><p>31. Bonekamp S., Halappa V.G., Geschwind J.F., et. al.: Unresectable hepatocellular carcinoma: MR imaging after intraarterial therapy. Part II. Response stratification using volumetric functional criteria after intraarterial therapy. Radiology 2013; 268: pp. 431-439.</p><li><p>32. Chapiro J., Wood L.D., Lin M., et. al.: Radiologic-pathologic analysis of contrast-enhanced and diffusion-weighted MR imaging in patients with HCC after TACE: diagnostic accuracy of 3D quantitative image analysis. Radiology 2014; 273: pp. 746-758.</p></ul></div><div class="post-tail-wrapper text-muted"><div class="post-meta mb-3"> <i class="far fa-folder-open fa-fw mr-1"></i> <a href='/categories/academic-radiology/'>Academic Radiology</a>, <a href='/categories/volume-25/'>Volume 25</a>, <a href='/categories/issue-11/'>Issue 11</a></div><div class="post-tags"> <i class="fa fa-tags fa-fw mr-1"></i> <a href="/tags/journals/" class="post-tag no-text-decoration" >Journals</a> <a href="/tags/general-radiology/" class="post-tag no-text-decoration" >General Radiology</a></div><div class="post-tail-bottom d-flex justify-content-between align-items-center mt-3 pt-5 pb-2"><div class="license-wrapper"> This post is licensed under <a href="https://creativecommons.org/licenses/by/4.0/"> CC BY 4.0 </a> by the author.</div><div class="share-wrapper"> <span class="share-label text-muted mr-1">Share</span> <span class="share-icons"> <a href="https://twitter.com/intent/tweet?text=Reproducibility%20of%20mRECIST%20in%20Measurement%20and%20Response%20Assessment%20for%20Hepatocellular%20Carcinoma%20Treated%20by%20Transarterial%20Chemoembolization%20-%20Radiology%20Tree&url=https%3A%2F%2Fclinicaltree.github.io%2Fposts%2Freproducibility-of-mrecist-in-measurement-and-response-assessment-for-hepatocellular-carcinoma-treat%2F" data-toggle="tooltip" data-placement="top" title="Twitter" target="_blank" rel="noopener" aria-label="Twitter"> <i class="fa-fw fab fa-twitter"></i> </a> <a href="https://www.facebook.com/sharer/sharer.php?title=Reproducibility%20of%20mRECIST%20in%20Measurement%20and%20Response%20Assessment%20for%20Hepatocellular%20Carcinoma%20Treated%20by%20Transarterial%20Chemoembolization%20-%20Radiology%20Tree&u=https%3A%2F%2Fclinicaltree.github.io%2Fposts%2Freproducibility-of-mrecist-in-measurement-and-response-assessment-for-hepatocellular-carcinoma-treat%2F" data-toggle="tooltip" data-placement="top" title="Facebook" target="_blank" rel="noopener" aria-label="Facebook"> <i class="fa-fw fab fa-facebook-square"></i> </a> <a href="https://t.me/share/url?url=https%3A%2F%2Fclinicaltree.github.io%2Fposts%2Freproducibility-of-mrecist-in-measurement-and-response-assessment-for-hepatocellular-carcinoma-treat%2F&text=Reproducibility%20of%20mRECIST%20in%20Measurement%20and%20Response%20Assessment%20for%20Hepatocellular%20Carcinoma%20Treated%20by%20Transarterial%20Chemoembolization%20-%20Radiology%20Tree" data-toggle="tooltip" data-placement="top" title="Telegram" target="_blank" rel="noopener" aria-label="Telegram"> <i class="fa-fw fab fa-telegram"></i> </a> <i id="copy-link" class="fa-fw fas fa-link small" data-toggle="tooltip" data-placement="top" title="Copy link" data-title-succeed="Link copied successfully!"> </i> </span></div></div></div></div></div><div id="panel-wrapper" class="col-xl-3 pl-2 text-muted"><div class="access"><div id="access-lastmod" class="post"><div class="panel-heading">Recently Updated</div><ul class="post-content pl-0 pb-1 ml-1 mt-2"><li><a href="/posts/neurometabolites-alteration-in-the-acute-phase-of-mild-traumatic-brain-injury-mtbi/">Neurometabolites Alteration in the Acute Phase of Mild Traumatic Brain Injury (mTBI)</a><li><a href="/posts/reinforcing-the-importance-and-feasibility-of-implementing-a-low-dose-protocol-for-ct-guided-biopsie/">Reinforcing the Importance and Feasibility of Implementing a Low-dose Protocol for CT-guided Biopsies</a><li><a href="/posts/rethinking-the-pgy-1-basic-clinical-year/">Rethinking the PGY-1 Basic Clinical Year</a><li><a href="/posts/single-injection-dual-phase-cone-beam-ct-dp-cbct-vascular-anatomy-assessment-and-occult-nodule-det/">Single Injection Dual-Phase Cone Beam CT (DP-CBCT) Vascular Anatomy Assessment and Occult Nodule Detection; Have We Reached the Focus?</a><li><a href="/posts/the-yellow-scale-is-superior-to-the-gray-scale-for-detecting-acute-ischemic-stroke-on-a-monitor-disp/">The Yellow Scale Is Superior to the Gray Scale for Detecting Acute Ischemic Stroke on a Monitor Display in Computed Tomography</a></ul></div><div id="access-tags"><div class="panel-heading">Trending Tags</div><div class="d-flex flex-wrap mt-3 mb-1 mr-3"> <a class="post-tag" href="/tags/general-radiology/">General Radiology</a> <a class="post-tag" href="/tags/journals/">Journals</a></div></div></div><div id="toc-wrapper" class="pl-0 pr-4 mb-5"><div class="panel-heading pl-3 pt-2 mb-2">Contents</div><nav id="toc"></nav></div><script src="https://cdn.jsdelivr.net/npm/tocbot@4.20.1/dist/tocbot.min.js"></script></div></div><div class="row"><div id="tail-wrapper" class="col-12 col-lg-11 col-xl-9 pl-3 pr-3 pr-xl-4 mt-5"><div id="related-posts" class="mb-2 mb-sm-4"><h3 class="pt-2 mb-4 ml-1" data-toc-skip>Further Reading</h3><div class="card-deck mb-4"><div class="card"> <a href="/posts/automated-breast-ultrasonography-abus-in-the-screening-and-diagnostic-setting/"><div class="card-body"> <em class="small" data-ts="1541005200" data-df="ll" > Oct 31, 2018 </em><h3 class="pt-0 mt-1 mb-3" data-toc-skip>Automated Breast Ultrasonography (ABUS) in the Screening and Diagnostic Setting</h3><div class="text-muted small"><p> Automated breast ultrasonography (ABUS) is a new imaging technology for automatic breast scanning through ultrasound. It was first developed to overcome the limitation of operator dependency and la...</p></div></div></a></div><div class="card"> <a href="/posts/change-in-nephrometry-scoring-in-small-renal-masses-4-cm-on-active-surveillance/"><div class="card-body"> <em class="small" data-ts="1541005200" data-df="ll" > Oct 31, 2018 </em><h3 class="pt-0 mt-1 mb-3" data-toc-skip>Change in Nephrometry Scoring in Small Renal Masses (<4 cm) on Active Surveillance</h3><div class="text-muted small"><p> Rationale and Objectives Prediction of growth, in particular knowing the possibility of aggressive cancer in small renal masses on active surveillance, remains poorly understood. The study was des...</p></div></div></a></div><div class="card"> <a href="/posts/comparison-of-natural-language-processing-rules-based-and-machine-learning-systems-to-identify-lumba/"><div class="card-body"> <em class="small" data-ts="1541005200" data-df="ll" > Oct 31, 2018 </em><h3 class="pt-0 mt-1 mb-3" data-toc-skip>Comparison of Natural Language Processing Rules-based and Machine-learning Systems to Identify Lumbar Spine Imaging Findings Related to Low Back Pain</h3><div class="text-muted small"><p> Rationale and Objectives To evaluate a natural language processing (NLP) system built with open-source tools for identification of lumbar spine imaging findings related to low back pain on magneti...</p></div></div></a></div></div></div><div class="post-navigation d-flex justify-content-between"> <a href="/posts/recognition-of-neonatal-lymphatic-flow-disorder/" class="btn btn-outline-primary" prompt="Older"><p>Recognition of Neonatal Lymphatic Flow Disorder</p></a> <a href="/posts/spectral-ct-imaging-of-lung-cancer/" class="btn btn-outline-primary" prompt="Newer"><p>Spectral CT Imaging of Lung Cancer</p></a></div></div></div></div><div id="search-result-wrapper" class="d-flex justify-content-center unloaded"><div class="col-12 col-sm-11 post-content"><div id="search-hints"><div id="access-tags"><div class="panel-heading">Trending Tags</div><div class="d-flex flex-wrap mt-3 mb-1 mr-3"> <a class="post-tag" href="/tags/general-radiology/">General Radiology</a> <a class="post-tag" href="/tags/journals/">Journals</a></div></div></div><div id="search-results" class="d-flex flex-wrap justify-content-center text-muted mt-3"></div></div></div></div><footer><div class="container pl-lg-4 pr-lg-4"><div class="d-flex justify-content-between align-items-center text-muted ml-md-3 mr-md-3"><div class="footer-left"><p class="mb-0"> © 2023 <a href="https://twitter.com/username">Clinical Team</a>. <span data-toggle="tooltip" data-placement="top" title="Except where otherwise noted, the blog posts on this site are licensed under the Creative Commons Attribution 4.0 International (CC BY 4.0) License by the author.">Some rights reserved.</span></p></div><div class="footer-right"><p class="mb-0">Using the <a href="https://jekyllrb.com" target="_blank" rel="noopener">Jekyll</a> theme <a href="https://github.com/cotes2020/jekyll-theme-chirpy" target="_blank" rel="noopener">Chirpy</a>.</p></div></div></div></footer><div id="mask"></div><a id="back-to-top" href="#" aria-label="back-to-top" class="btn btn-lg btn-box-shadow" role="button"> <i class="fas fa-angle-up"></i> </a><div id="notification" class="toast" role="alert" aria-live="assertive" aria-atomic="true" data-animation="true" data-autohide="false"><div class="toast-header"> <button type="button" class="ml-2 ml-auto close" data-dismiss="toast" aria-label="Close"> <span aria-hidden="true">&times;</span> </button></div><div class="toast-body text-center pt-0"><p class="pl-2 pr-2 mb-3">A new version of content is available.</p><button type="button" class="btn btn-primary" aria-label="Update"> Update </button></div></div><script src="https://cdn.jsdelivr.net/npm/simple-jekyll-search@1.10.0/dest/simple-jekyll-search.min.js"></script> <script> SimpleJekyllSearch({ searchInput: document.getElementById('search-input'), resultsContainer: document.getElementById('search-results'), json: '/assets/js/data/search.json', searchResultTemplate: '<div class="pl-1 pr-1 pl-sm-2 pr-sm-2 pl-lg-4 pr-lg-4 pl-xl-0 pr-xl-0"> <a href="{url}">{title}</a><div class="post-meta d-flex flex-column flex-sm-row text-muted mt-1 mb-1"> {categories} {tags}</div><p>{snippet}</p></div>', noResultsText: '<p class="mt-5">Oops! No results found.</p>', templateMiddleware: function(prop, value, template) { if (prop === 'categories') { if (value === '') { return `${value}`; } else { return `<div class="mr-sm-4"><i class="far fa-folder fa-fw"></i>${value}</div>`; } } if (prop === 'tags') { if (value === '') { return `${value}`; } else { return `<div><i class="fa fa-tag fa-fw"></i>${value}</div>`; } } } }); </script> <script src="https://cdn.jsdelivr.net/combine/npm/magnific-popup@1.1.0/dist/jquery.magnific-popup.min.js,npm/lazysizes@5.3.2/lazysizes.min.js,npm/clipboard@2.0.11/dist/clipboard.min.js"></script> <script src="https://cdn.jsdelivr.net/combine/npm/dayjs@1.11.6/dayjs.min.js,npm/dayjs@1.11.6/locale/en.min.js,npm/dayjs@1.11.6/plugin/relativeTime.min.js,npm/dayjs@1.11.6/plugin/localizedFormat.min.js"></script> <script defer src="/assets/js/dist/post.min.js"></script> <script src="https://cdn.jsdelivr.net/npm/bootstrap@4.6.2/dist/js/bootstrap.bundle.min.js"></script> <script defer src="/app.js"></script> <script defer src="https://www.googletagmanager.com/gtag/js?id=G-L66SLQK23K"></script> <script> document.addEventListener("DOMContentLoaded", function(event) { window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'G-L66SLQK23K'); }); </script>
